OM202JP Clinical Study of KNP2002
A Phase II Clinical Study of KNP2002 Ointment in Patients With Common Warts (OM202JA)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Katsuhiko Sato, Ph.D.
- Phone Number: +81-3-6264-9604
- Email: k.sato@kinopharma.com
Study Locations
-
-
-
Osaka, Japan, 537-0013
- Hayami Dermatology
-
-
Gunma
-
Maebashi, Gunma, Japan, 371-0046
- Kawaharamachi Dermatology
-
-
Hyogo
-
Himeji, Hyogo, Japan, 672-8084
- Tetsuya Dermatology
-
Kobe, Hyogo, Japan, 657-0027
- Takashima Dermatology
-
Kobe, Hyogo, Japan, 657-0065
- Nishino Dermatology Clinic
-
-
Kanagawa
-
Yokohama, Kanagawa, Japan, 220-6208
- Queen's Square, Dermatology, Allergy
-
Yokohama, Kanagawa, Japan, 240-0013
- Asai Dermatology Clinic
-
-
Osaka
-
Sakai, Osaka, Japan, 593-8301
- Okawa Dermatology Clinic
-
-
Tochigi
-
Utsunomiya, Tochigi, Japan, 321-2471
- Sugai Dermatology Parkside Clinic
-
-
Tokyo
-
Arakawa-Ku, Tokyo, Japan, 116-0003
- Tsunoda Clinic
-
Katsushika-Ku, Tokyo, Japan, 125-0041
- Sugisawa Dermatology Clinic
-
Kita-Ku, Tokyo, Japan, 115-0045
- Igarashi Clinic
-
Koto-Ku, Tokyo, Japan, 136-0074
- Maruyama Dermatology Clinic
-
Nakano-Ku, Tokyo, Japan, 164-0001
- Todoroki Dermatology Clinic
-
Setagaya-Ku, Tokyo, Japan, 157-0062
- Okuda Dermatology Clinic
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Subjects aged 15 to 49 years old
- Subjects with common warts on the upper or lower limb
- Subjects who agree to contraception from obtaining consent to 4 weeks after the end of administration
- Subjects who have given their voluntary written consent to participate in this clinical trial
Exclusion Criteria:
- Subjects with 5 or more warts on the upper or lower limbs
- Subjects who are scheduled to undergo treatment such as physical therapy or chemotherapy for warts
- Subjects with a history of allergy to topical skin preparations
- Subjects with a history of malignant tumor within 5 years before administration of study drug
- Subjects with any of the following diseases: Malignant tumor; Serious heart disease; Poorly controlled diabetes/hypertension
- Women who are pregnant, may become pregnant, or are breastfeeding
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Low dose group
Topical administration of low dose of KPN2002
|
Dairy topical administration for 12 weeks
Other Names:
|
|
Experimental: Middle dose group
Topical administration of middle dose of KPN2002
|
Dairy topical administration for 12 weeks
Other Names:
|
|
Experimental: High dose group
Topical administration of high dose of KPN2002
|
Dairy topical administration for 12 weeks
Other Names:
|
|
Placebo Comparator: Placebo group
Topical administration of placebo
|
Dairy topical administration for 12 weeks
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in wart area
Time Frame: At 16 weeks after starting administration
|
Percent change in wart area from baseline
|
At 16 weeks after starting administration
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in wart area over time
Time Frame: At 4, 8, 12, and 16 weeks after starting administration
|
Percent change in wart area from baseline
|
At 4, 8, 12, and 16 weeks after starting administration
|
|
Wart improvement rate
Time Frame: At 4, 8, 12, and 16 weeks after starting administration
|
Wart improvement rate categorized by rate of change in wart area
|
At 4, 8, 12, and 16 weeks after starting administration
|
|
Wart disappearance rate
Time Frame: Up to 16 weeks after starting administration
|
Proportion of patients with warts disappearing
|
Up to 16 weeks after starting administration
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- OM202JA
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.